recombinant mouse interferon γ ifn γ  (R&D Systems)

Journal: Redox Biology

Article Title: A novel photosensitizer-based photodynamic therapy reprograms the Kynurenine–AhR axis to boost antitumor immunity in breast cancer

doi: 10.1016/j.redox.2026.104171

Figure Lengend Snippet: DTP-PDT attenuates the IDO–Kyn–AhR axis and relieves immune-suppression in the TME. (A-D) Targeted metabolomics analysis of Trp, Kyn, QA, and 5-HT in cell samples. (E) Targeted metabolomics of Kyn in tumor tissue samples. (F) Levels of Kyn in culture supernatants after the indicated various treatments under IFN-γ priming (n = 3). (G) Representative immunofluorescence images of tumor sections stained for CD3 (green), AhR (red), and DAPI (blue). Scale bar = 20 μm. (H) RT-qPCR analysis of Cyp1a1, Cyp1b1, and Ahrr mRNA expression in tumor-infiltrating CD3 + T cells (n = 4). (I-J) Proportion of intratumoral CD8 + T cells (gated on CD3 + T cells, n = 5). (K-L) Proportion of intratumoral Treg cells (gated on CD3 + CD4 + Foxp3 + T cells, n = 5). (M) Representative immunofluorescence images of tumor sections stained for CD3 (green), AhR (red), and DAPI (blue) in the Kyn rescue experiment. Scale bar = 20 μm. (N) RT-qPCR analysis of Cyp1a1, Cyp1b1, and Ahrr mRNA expression in tumor-infiltrating CD3 + T cells from the Kyn rescue experiment (n = 4). (O–P) Proportion of intratumoral CD8 + T cells in the Kyn rescue experiment (gated on CD3 + T cells, n = 5). (Q-R) Proportion of intratumoral Treg cells in the Kyn rescue experiment (gated on CD3 + CD4 + Foxp3 + T cells, n = 5). Data are shown as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: 4T1 cells (5 × 10 5 cells/well) were seeded in 6-well plates and allowed to adhere for 24 h. To activate IDO1 activity, cells were pretreated with recombinant mouse interferon-γ (IFN-γ) (50 ng/mL, 485-MI, R&D System) for 24 h. After IFN-γ priming, cells were treated with DTP-PDT and/or the IDO1 inhibitor (NLG919, Aladdin).

Techniques: Immunofluorescence, Staining, Quantitative RT-PCR, Expressing

Journal: Cell Reports Medicine

Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

doi: 10.1016/j.xcrm.2026.102754

Figure Lengend Snippet: Splenic immune responses mediated by STNvac (A) Schematic illustration showing that STNvac promotes DC activation and antigen-specific T cell induction. (B) Representative immunofluorescence images showing the localization of CD11c + DCs (green) and Cy5-labeled mRNA (red) in the spleen of C57BL/6 mouse 6 h after intravenous administration of LNP-mRNA Cy5 (N/P = 0.5). MZ, marginal zone; WP, white pulp; RP, red pulp. Scale bars, 50 μm. (C and D) Ex vivo IFN-γ ELISpot analysis of STNvac-immunized mice. (C) Representative ELISpot images. (D) Quantification of IFN-γ spot-forming units. (E and F) Flow cytometry analysis of splenic immune cell activation after 48 h of STNvac administration. (E) Representative contour plots. (F) Quantitative analysis. Statistics: one-way ANOVA for (D) and (F). Mean ± SD ( n = 3 biological replicates). Significance levels: ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. See also and .

Article Snippet: Mouse IFN-γ ELISpot Kit , Mabtech , Cat#3321-4AST-2.

Techniques: Activation Assay, Immunofluorescence, Labeling, Ex Vivo, Enzyme-linked Immunospot, Flow Cytometry

Journal: Cell Reports Medicine

Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

doi: 10.1016/j.xcrm.2026.102754

Figure Lengend Snippet: Therapeutic efficacy and tumor microenvironment (TME) alterations induced by STNvac treatment (A) Schematic illustration of the treatment schedule ( n = 7 mice per group). (B) Bioluminescence images showing tumor burden in orthotopic HCC-bearing mice receiving PBS (G1), Neo-mRNA (G2), LNP-scramble mRNA (G3), or STNvac (G4) during the 8-week observation period. (C) Total bioluminescence flux for individual mice corresponding to (B). (D) Survival curves of mice in different treatment groups. (E) Mean body weight of mice monitored throughout the study period, showing no significant loss. (F and G) Flow cytometry analysis of tumor-infiltrating immune cells collected 72 h after the final vaccination (day 10): (F) quantitative analysis ( n = 5 biological replicates) and (G) representative contour plots. (H) Immunofluorescence staining of CD4 + and CD8 + T cells in dissected tumor sections. Scale bars, 50 μm. (I) Cytokine levels (IL-12, IFN-γ, and TNF-α) in tumor lysates measured by ELISA ( n = 5 biological replicates, day 10). Statistics: one-way ANOVA for (F) and (I); log rank (Mantel-Cox) test for (D). Mean ± SD. Significance levels: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001. See also and .

Article Snippet: Mouse IFN-γ ELISpot Kit , Mabtech , Cat#3321-4AST-2.

Techniques: Drug discovery, Flow Cytometry, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay

Journal: Cell Reports Medicine

Article Title: Spleen-targeted neoantigen mRNA vaccine induces ISG15 + CD8 + T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma

doi: 10.1016/j.xcrm.2026.102754

Figure Lengend Snippet: STNvac-induced enhancement of tumor infiltration, antigen-presenting capacity, and cytotoxic activity of ISG15 + CD8 + T cells (A) UMAP visualization of single-cell transcriptomes from CD45 + immune cells. (B) Relative proportions of major immune cell populations in PBS and STNvac groups. (C) UMAP visualization of T cell clusters from PBS and STNvac groups. (D) Relative proportions of different T cell clusters in PBS and STNvac groups. (E) Violin plots showing expression levels of T cell function markers across T cell clusters. (F) Representative multicolor immunofluorescence images of tumor sections showing co-localization of ISG15 + CD8 + T cells with GZMB and IFN-γ in PBS and STNvac groups. Scale bars, 50 μm. (G) Quantification of ISG15 + CD8 + T cell density co-expressing GZMB and IFN-γ, corresponding to (F). Unpaired two-tailed t test; ∗p < 0.05. Mean ± SD ( n = 3 biological replicates). (H) Comparative GO and KEGG pathway enrichment analyses of ISG15 + CD8 + T cells between PBS and STNvac groups. (I) Kaplan-Meier curves showing 5-year overall survival (OS) and progression-free survival (PFI) for HCC patients in TCGA: LIHC cohort stratified by ISG15 + CD8 + T cell signatures. See also and .

Article Snippet: Mouse IFN-γ ELISpot Kit , Mabtech , Cat#3321-4AST-2.

Techniques: Activity Assay, Single Cell, Expressing, Cell Function Assay, Immunofluorescence, Two Tailed Test